Ying Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Qi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bokai Ma
Institute of Analysis and Testing, Beijing Academy of Science and Technology (Beijing Center for Physical and Chemical Analysis), Beijing 100089, PR China
1 shared publication- Guangle Niu
Beijing Institute of Technology
1 shared publication Jinge Zhao
Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Key Laboratory of Cluster Science of Ministry of Education, Beijing Key Laboratory of Photoelectronic/Electro-photonic Conversion Materials, School of Chemistry and Chemical Engineering, Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, PR China
1 shared publication- Juan Xu
NHC Key Laboratory of Reproductive Health Engineering Technology Research, Haidian district, No.12, Da Hui Si Road, Beijing 100081, China; National Research Institute for Family Planning, Haidian district, No.12, Da Hui Si Road, Beijing 100081, China
1 shared publication Kai Han
Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Key Laboratory of Cluster Science of Ministry of Education, Beijing Key Laboratory of Photoelectronic/Electro-photonic Conversion Materials, School of Chemistry and Chemical Engineering, Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, PR China
1 shared publication- Limin Zhang
Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering Ministry of Industry and Information Technology Key Laboratory of Cluster Science of Ministry of Education Beijing Key Laboratory of Photoelectronic/Electro‐photonic Conversion Materials School of Chemistry and Chemical Engineering Tangshan Research Institute Beijing Institute of Technology Beijing 100081 P.R. China
1 shared publication
Latest Publications
- 24 January 2025
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 27 (8) , 1146-1156
Innovative aminoglutethimide co-crystals: synthesis, characterization, and insights into molecular interactions
Aminoglutethimide (AG), a Biopharmaceutical Classification System II (BCSII) drug, is approved for treating certain patients with Cushing's syndrome and breast cancer. However, it is technically limited to clinical application due to poor aqueous solubility. The water solubility of AG can be enhanced through the utilization of the co-crystal method. To screen AG co-crystals, this work employed liquid-assisted grinding and slow solvent evaporation methods. Three novel co-crystals of AG were successfully synthesized based on NH2–COOH supramolecular synthon theory. All co-crystals exhibited higher apparent solubility than pure AG in the dissolution experiments. The intermolecular interactions of the co-crystals were examined using single crystal X-ray diffraction along with other analytical methods to determine their crystal structures. The formation of co-crystals was dominated by N–H⋯O hydrogen bonds in molecular electrostatic potential (MEP) analysis. To further explore and visualize the intermolecular interactions that form co-crystals, Hirshfeld surface (HS) analyses and independent gradient model based on Hirshfeld partition (IGMH) analysis were applied. It was found that the van der Waals (vdW) force is another main driving force, working in conjunction with hydrogen bonds to form basic units of AG co-crystals. In addition, toxicity tests on liver and kidney organoids showed that three new co-crystals did not cause more serious toxicity than pure AG. Overall, this work has provided the structural analysis of three newly formed AG co-crystals, offering an insight into intermolecular interactions of co-crystals at the molecular level.
- 24 January 2025
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 27 (8) , 1146-1156
Innovative aminoglutethimide co-crystals: synthesis, characterization, and insights into molecular interactions
Aminoglutethimide (AG), a Biopharmaceutical Classification System II (BCSII) drug, is approved for treating certain patients with Cushing's syndrome and breast cancer. However, it is technically limited to clinical application due to poor aqueous solubility. The water solubility of AG can be enhanced through the utilization of the co-crystal method. To screen AG co-crystals, this work employed liquid-assisted grinding and slow solvent evaporation methods. Three novel co-crystals of AG were successfully synthesized based on NH2–COOH supramolecular synthon theory. All co-crystals exhibited higher apparent solubility than pure AG in the dissolution experiments. The intermolecular interactions of the co-crystals were examined using single crystal X-ray diffraction along with other analytical methods to determine their crystal structures. The formation of co-crystals was dominated by N–H⋯O hydrogen bonds in molecular electrostatic potential (MEP) analysis. To further explore and visualize the intermolecular interactions that form co-crystals, Hirshfeld surface (HS) analyses and independent gradient model based on Hirshfeld partition (IGMH) analysis were applied. It was found that the van der Waals (vdW) force is another main driving force, working in conjunction with hydrogen bonds to form basic units of AG co-crystals. In addition, toxicity tests on liver and kidney organoids showed that three new co-crystals did not cause more serious toxicity than pure AG. Overall, this work has provided the structural analysis of three newly formed AG co-crystals, offering an insight into intermolecular interactions of co-crystals at the molecular level.
- 14 November 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 24 (48) , 15396-15405
Harnessing Cross-strand π–π Interlocking for Synergistic Enhancement of Immune Checkpoint Blocking and Ferroptosis
The dynamic nature of noncovalent bonds in peptide self-assembly allows for selective accommodation of guest molecules. However, it remains unclear how to harness coassembly to reinforce the host peptides and simultaneously improve the application defects of guest molecules. This study aims to achieve supramolecular synergy between the host and guest, further expanding the functional space of the hybrid nanostructures. Herein, we utilized the aromatic regions present in β-sheet peptides to accommodate aromatic molecules, forming long-range nanotubes (NQ40@AIF) through a unique 'cross-strand π-π interlocking'. This strategy not only stabilizes the coassembly effectively but also synergizes the biological functions of the host and guest molecules. Moreover, due to the chemical diversity of the coassembled NQ40@AIF, it exhibits advantages in tumor combination therapy, achieving effective synergy between ferroptosis and immune checkpoint blocking. This work provides a minimalistic strategy for constructing peptide nanostructures with complex functionalities.
- 14 November 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 24 (48) , 15396-15405
Harnessing Cross-strand π–π Interlocking for Synergistic Enhancement of Immune Checkpoint Blocking and Ferroptosis
The dynamic nature of noncovalent bonds in peptide self-assembly allows for selective accommodation of guest molecules. However, it remains unclear how to harness coassembly to reinforce the host peptides and simultaneously improve the application defects of guest molecules. This study aims to achieve supramolecular synergy between the host and guest, further expanding the functional space of the hybrid nanostructures. Herein, we utilized the aromatic regions present in β-sheet peptides to accommodate aromatic molecules, forming long-range nanotubes (NQ40@AIF) through a unique 'cross-strand π-π interlocking'. This strategy not only stabilizes the coassembly effectively but also synergizes the biological functions of the host and guest molecules. Moreover, due to the chemical diversity of the coassembled NQ40@AIF, it exhibits advantages in tumor combination therapy, achieving effective synergy between ferroptosis and immune checkpoint blocking. This work provides a minimalistic strategy for constructing peptide nanostructures with complex functionalities.